NeuroPace Q2 revenue $16.5M (+62% YoY); raises FY 2023 guidance to $59-61M

NeuroPace Inc

2023-Q2 EPS reported -$0.77 revenue$30,982,000

Q2 revenue $16.5M, up 62% YoY and 14% QoQ; net loss narrowed to $9.1M from $12.7M YoY.
Full-year 2023 revenue guidance raised to $59-61M (30-34% growth), from prior $52-54M.
Cash burn reduced to $4M in Q2 from $9.8M in Q1; cash and investments $63.6M at June 30.
NAUTILUS trial enrollment on track; full enrollment expected Q1 2024 for generalized epilepsy.
Gross margin 72.5%; operating expenses flat YoY; DIXI product distribution contributed to revenue.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NeuroPace Inc reported full year 2023 results: revenue $59 million to $61 million. Guidance raised.

Period: full year 2023
Revenue: $59 million to $61 million
Guidance: raised
Result: guidance update

Exact text from the filing

Increased total revenue guidance to range between $59 million and $61 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NeuroPace Inc reported the second quarter ended June 30, 2023 results: revenue $16.5 million, net income $9.1 million.

Period: the second quarter ended June 30, 2023
Revenue: $16.5 million
Net income: $9.1 million
Result: reported results

Exact text from the filing

Total revenue was $16.5 million in the second quarter of 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.